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a  b  s  t  r  a  c  t
Beginning  in  the  20th  century  with  the  consideration  of  the  seven-valent  pneumococcal  conjugate  vaccine
in the  US,  the  cost  effectiveness  became  a topic  of  discussion  when  this  vaccine  was  being considered
for  universal  use  by  the  US  Advisory  Committee  on  Immunization  practices  (ACIP).  In 2008,  the  ACIP
began using  formal  criteria  for the  presentation  of such  data  and  their  inclusion  in  ACIP  discussions.
More  recently,  the  US  Institute  of  Medicine  has  recommended  that health  economic  considerations  play  a
primary  role  in  the  prioritization  of  future  vaccine  for  development.  However,  such  analyses  can  be  biased
towards  vaccines  that  provide  economic  beneﬁt  rather  than  those  that  reduce  severe  morbidity  and
mortality.  This  is  because  the  economic  impact  of  minor  common  events  that result  in  medical  utilization
or  time  lost  from  work  for parents  can  outweigh  the  economic  impact  of  severe  morbidity  and  mortality.
Thus  diseases  with  a low  mortality  and  morbidity  but  with  a common  clinical  manifestation  such  as  the
common  cold  could  be  prioritized  over  vaccines  against  diseases  such  as  meningococcal  sepsis  where
the morbidity  and  mortality  associated  with  each  case  is very  high,  but  there  is  no  associated  common
clinical syndrome.  Thus  the  use  of  cost  effectiveness  analyses  as a  ‘gating  criteria’  to  decide  which  vaccines
should be  developed  or  routinely  used  runs  the  risk  of  transforming  vaccines  into  primarily  a tool  for
achieving cost  savings  within  the  health  care  system  rather  than  a  public  health  intervention  targeting
human  suffering,  death  and  disability.  It  is  the  purpose  of  this  article  to  review  the  framework  under
which  health  economic  evaluations  can  be  undertaken,  to  review  the  experience  with  and  reliability  of
such  analyses,  and  to  discuss  the  potential  negative  implications  of  the  use  of  health  economic  analyses
as a  primary  decision  making  tool.© 2013 The Author. Published by Elsevier Ltd. All rights reserved.
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. Introduction
At the time of the development of the smallpox vaccine by
diseases were targeted based upon their morbidity and mortal-
ity rather than their cost saving potential leading to vaccines for
diphtheria, pertussis, tetanus and later polio, measles, mumps andenner in 1796, the focus of the public was on high mortality of
mallpox and on the safety and the efﬁcacy of Jenner’s vaccine.
he cost effectiveness of his approach was not a consideration [1].
n fact, at the beginning of the modern vaccine era in the 1940s,
 This is an open-access article distributed under the terms of the Creative
ommons Attribution License, which permits unrestricted use, distribution, and
eproduction in any medium, provided the original author and source are credited.
∗ Tel.: +1 5138030747.
E-mail addresses: stevblack@gmail.com, Steven.Black1@cchmc.org
264-410X/$ – see front matter ©  2013 The Author. Published by Elsevier Ltd. All rights r
ttp://dx.doi.org/10.1016/j.vaccine.2013.08.008rubella. Beginning in the 20th century and with the consideration
of the seven-valent pneumococcal conjugate vaccine in the US, the
cost effectiveness of this vaccine became a topic of discussion when
it was being considered for universal use by the US Advisory Com-
mittee on Immunization practices (ACIP). In 2008, the ACIP began
using formal criteria for the presentation of such data and their
inclusion in ACIP discussions [2]. More recently, the US Institute of
Medicine has recommended that health economic considerations
play a primary role in the prioritization of future vaccine for devel-
opment [3]. It is the purpose of this article to review the framework
under which health economic evaluations can be undertaken, to
eserved.
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eview the experience with and reliability of such analyses, and
o discuss the potential negative implications of the use of health
conomic analyses as a primary decision making tool.
. Types of health economic studies relevant to vaccine
valuation
The methods most commonly applied to the health economic
valuation of vaccines are cost-beneﬁt, cost-effectiveness and cost-
tility. While a full description of each of these methods is beyond
he scope of this article, summaries of these methods have been
repared elsewhere so they will only be summarized here to put
he later discussion in context [4].
A cost effectiveness analysis is a comparison of the costs and
utcomes of two or more health interventions. For a new vaccine
his is commonly a comparison of no vaccine (status quo) versus
he introduction of the new vaccine. In such an analysis, the cost-
ffectiveness of a vaccine is expressed as the cost per unit gain in
ealth [4]. The most commonly used outcome measure for such an
nalysis is the QALY or quality adjusted life year. This measure takes
nto account the cost of the intervention, the impact on quality of
ife or prevention of death and the incidence of the disease. Thus a
accine for a common disease with low impact on quality of life can
ave the same cost effectiveness as an uncommon disease with high
orbidity and mortality. This can lead to some counter intuitive
ecisions, as we will see later.
A cost beneﬁt analysis is similar to a cost effectiveness analy-
is, but in this type of analysis, both the cost and the beneﬁts are
xpressed in a monetary unit such as dollars or euros. This approach
equires assigning a monetary value to outcomes such as years of
ife lost due to death, partial disabilities such a deafness, blind-
ess or retardation, and disﬁgurement. An adjustment for the time
alue of money is usually made with the frame of reference is usu-
lly net present value. Because of inﬂation, this approach requires
iscounting the value of dollars saved in the future. This is impor-
ant in consideration of vaccines because while costs usually are
ncurred “up front”, the beneﬁts may  not accrue for months or years
5]. However, for very effective vaccines, freedom from disease will
e worth more to the health care system than the individual case
nalysis would indicate. This is because public health resources
edicated to monitoring and development of control strategies can
e allocated to other areas. However, it must be recognized that the
eed for such estimates can limit the generalizability of the conclu-
ions of a given cost-beneﬁt model to the time and place where it
as conducted.
A cost-utility analysis is similar to a cost effectiveness analy-
is in that outcomes are expressed in the cost of an intervention
o provide an improvement in quality of life. While the measure
ere is similar to that of a cost-effectiveness analysis, the prod-
ct of the analysis is a number that then can be used to compare
he cost-utility of other unrelated health expenditures. That is, the
ost-utility of a vaccine can be compared to a clean water interven-
ion or mammography screening [6]. This has been used in some
ettings, such as the UK, to introduce a cost-utility “threshold” for
he evaluation of new interventions above which the event is less
ikely to be funded [7].
. Potential impact of the use of vaccine health economic
nalyses upon public health
Common to all health economic evaluations is the assumption
hat the higher the cost-effectiveness of a vaccine, the higher pri-
rity it should be given for development and then generalized use.
s can be seen in Table 1, this can lead to a situation where very
ommon diseases such as the common cold or rotavirus infection013) 6046– 6049 6047
in developed countries can be prioritized for introduction into a
national immunization program because of their economic ben-
eﬁt rather than their impact upon mortality and morbidity. That
is, a little inconvenience or minor malaise in a large number of
individuals can outweigh signiﬁcant morbidity or mortality in a
smaller number of people. A good example of this conundrum is
the common cold. Here we  have an entity which is very com-
mon  with most people experiencing at least one episode per year
and which results in discomfort as well as a considerable expendi-
ture for medications or other over the counter remedies. However,
there are no deaths or long-term disabilities due to the com-
mon  cold. If we  compare this to an uncommon infection such
as meningococcal disease which has a 10% mortality and leaves
approximately 50% of individuals with long term disabilities, the
development of a vaccine against the common cold and its rou-
tine use would likely be more cost effective than the use of a
meningococcal vaccine. Perhaps a more relevant example is that
of rotavirus infection in developed countries such as countries in
Europe or the US and Canada. Rotavirus infection is almost univer-
sal by two years of age. However, death is virtually unknown as
is long-term disability in the developed country setting. However,
since most parents seek medical attention for their child’s gas-
troenteritis and since hospitalizations for dehydration can occur,
the economic cost of the disease is high. Again, if one evaluates
the cost-effectiveness of rotavirus vaccine in the UK or the US  as
compared to meningococcal vaccination, there is no contest and
rotavirus vaccination is more cost effective. However, in terms of
prevention of deaths and morbidity vaccination against meningo-
coccal disease is clearly preferable. One way of approaching the
issue of the use of cost-effectiveness analyses in vaccine decision-
making is to ask, “What are we trying to accomplish?” If the goal is
to maximize cost saving in health care, then vaccines become a tool
to achieve this outcome. If the goal is to minimize human suffer-
ing and to prevent loss of life, then the use of a cost-effectiveness
threshold for public health interventions such as vaccines is
problematic.
In Fig. 1, we  can see a schematic representation of ﬁve diseases
and the vaccines that have been developed for prevent them. The
disease outcome information is presented in the form of a pyra-
mid  while the supporting data is shown below the diagram. The
tip of the pyramid includes less common but more severe events
such as mortality and long-term disability. More common mani-
festations of the disease are represented in the wide portion of the
pyramid. In looking at the rotavirus example discussed above, we
can see that there are an estimated 20 deaths per year in the US,
but that there are 600,000 outpatient medical visits and a moder-
ate amount of time lost from work by parents. For pneumococcal
disease, we  see an interesting hybrid. The number of deaths due
to pneumococcal disease (before vaccine introduction) was essen-
tially equivalent to that for meningococcal disease with sequelae
being less common than with meningococcal disease. However, the
pneumococcus also causes a common disease syndrome – otitis
media-that drove the cost effectiveness of pneumococcal conju-
gate vaccine programs in pre-implementation models. Similarly for
varicella, death and sequelae of infection were relatively uncom-
mon  but the vaccine was considered to be cost-effective because
the disease was  common and while the disease was  mild, it almost
always resulted in some medical utilization. If we look again at
the meningococcus, we  can see that although it results in about the
same number of deaths as pneumococcal infection in childhood and
more sequelae, because it is not associated with a common mild dis-
ease syndrome as well, it will not fare well in a cost-effectiveness
analysis.
One can view this as an “iceberg effect” in which a common
disease syndrome, largely below the surface in terms of mortality
or morbidity, ﬂoats the vaccine program.
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Table 1
Qualitative comparison of the impact of ﬁve diseases on mortality, morbidity, hospital utilization, outpatient utilization and parental loss of time from work.
Disease Mortality with
optimal treatment
Morbidity with
optimal treatment
Hospital
utilization
Outpatient
utilization
Parental time
lost from Work
Meningococcal sepsis/meningitis ++++ ++++ + − −
Hib  meningitis ++++ +++ ++ ++ +
Rotavirus GE − − +++ ++++ ++++
Viral  URI − − − +++ +++
Otitis  media − + − ++++ ++++
The symbols −, and + to ++++ are meant to qualitatively represent an absent of impact or gradations of impact with more “+”s representing a higher impact.
Fig. 1. Comparative disease burden for ﬁve vaccine preventable diseases.
Annual Events Pre-Vaccine Introduction in US Children and Adolescents 18 years of age and younger.
EVENT Number of Events
Deaths 160 [11] 160 [12] 20-60 [13] 100–150 [14] 600 [15]
Long Term Sequelae 200 [16] 195 [17] Rare 20 [14] 2600 [18]
Outpatient Visits Low >1 million cases 600,000 [13] 480,000 [14] Low
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Contribution of Time Lost from
Work by Parents to CE analysis
Low Moderate 
As can be seen in Table 1, if one uses cost-effectiveness as
 primary criteria for decision making regarding vaccine devel-
pment and implementation, one would favor development of
 vaccine against otitis media and viral URI rather than one for
ib meningitis or meningococcal sepsis. This would be beneﬁcial
or the health care system and society economically, but would
ot target relatively uncommon causes of signiﬁcant mortality or
orbidity.
What has been the experience in using cost effectiveness anal-
ses for vaccine decision-making?
As mentioned in the introduction, discussions regarding cost-
ffectiveness took place during the ACIP discussions regarding
-valent pneumococcal vaccine. There were members of the com-
ittee who voiced concerns that the vaccine was not cost effective
ased upon an estimated $80,000 per life year saved [8]. This dis-
ussion illustrates another important point. While we now know
hat pneumococcal conjugate vaccine induces widespread indirect
r “herd” effect and also are associated with serotype replacement,
his was not known at the time the cost-effectiveness model was
resented. When these indirect effects became apparent, a cost
ffectiveness analysis conducted ﬁve years after introduction esti-
ated the cost per life year saved to be $7500 [9]. Clearly, the
re-licensure projection widely underestimated the true impact
nd cost effectiveness of the vaccine and could have led to an inap-
ropriate decision regarding vaccine introduction.Moderate High Low
Cost effectiveness models are only as good as the data utilized
and the assumptions made. Often, the impact of a new vaccine
against a possible multiplicity of outcomes is not known. If the
model is based upon a clinical trial, efﬁcacy has usually only been
measured against one or two outcomes and there is uncertainty
regarding the true estimate of efﬁcacy and the generalizability of
the results to a real world situation where partial vaccination and
late receipt of doses is common. Since clinical trials take place in
small subsets of the general population, it is not possible to reliably
assess potential indirect effects.
When meningococcal C vaccination was  introduced in the UK,
although there was  hope that indirect effects would be seen, all
that was known was that the vaccine was safe and immunogenic.
Whether indirect effects would be seen and the extent of this poten-
tial effect was not known until after vaccine introduction when
indirect effects resulted in the virtual elimination of this disease
in the UK. If cost-effectiveness had been taken as a “gold standard”
requirement for pneumococcal conjugate vaccine, it is possible that
the vaccine may  not have been introduced into the US population
and we would not have learned its true impact. Similarly in the UK,
if decisions had been made based only upon what was known about
meningococcal C vaccine rather than its likely potential impact, the
opportunity to prevent signiﬁcant morbidity and mortality could
have been lost. As Weimer stated in his text Policy Analysis: Con-
cepts and Practice, “An analyst using CBA should recognize that
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erfect evaluation of all present and future costs and beneﬁts is dif-
cult, and while CBA can offer a well-educated estimate of the best
lternative, perfection in terms of economic efﬁciency and social
elfare are not guaranteed [10].
. Conclusion
While consideration of cost-effectiveness is an important com-
onent in the evaluation of vaccines, use of cost-effectiveness
odels can be problematic if used as an absolute criterion. This
s both because of the in-exact nature of models which necessarily
nclude incomplete data and incorrect assumptions prior to vaccine
ntroduction, but also because such models tend to favor diseases
hich have a common mild component even though such diseases
ay  not be signiﬁcant causes of morbidity or mortality. The use of
ost-effectiveness analyses as a “gating criteria” to decide which
accines should be developed or routinely used runs the risk of
ransforming vaccines into primarily a tool for achieving cost sav-
ngs within the health care system rather than a public health
ntervention targeting human suffering, death and disability. If our
rimary goal is to prevent disease morbidity and mortality, then
ost-effectiveness analyses must assume a secondary role in our
accine decision-making processes.
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